GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (NAS:PHAR) » Definitions » EPS (Diluted)

Pharming Group (Pharming Group) EPS (Diluted) : $-0.16 (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Pharming Group EPS (Diluted)?

Pharming Group's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.05. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.16.

Pharming Group's EPS (Basic) for the three months ended in Dec. 2023 was $-0.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.16.

Pharming Group's EPS without NRI for the three months ended in Dec. 2023 was $-0.05. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.16.

During the past 12 months, Pharming Group's average EPS without NRIGrowth Rate was -825.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Pharming Group's highest 3-Year average EPS without NRI Growth Rate was 58.60% per year. The lowest was -59.20% per year. And the median was 26.30% per year.


Pharming Group EPS (Diluted) Historical Data

The historical data trend for Pharming Group's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group EPS (Diluted) Chart

Pharming Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 0.55 0.23 0.19 -0.16

Pharming Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.22 -0.19 0.02 0.06 -0.05

Competitive Comparison of Pharming Group's EPS (Diluted)

For the Biotechnology subindustry, Pharming Group's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharming Group's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's PE Ratio distribution charts can be found below:

* The bar in red indicates where Pharming Group's PE Ratio falls into.



Pharming Group EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Pharming Group's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-10.548-0)/72.546
=-0.15

Pharming Group's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-3.123-0)/87.686
=-0.04

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharming Group  (NAS:PHAR) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Pharming Group EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Pharming Group's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharming Group (Pharming Group) Business Description

Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on developing and producing human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. The revenue is generated from the United States.

Pharming Group (Pharming Group) Headlines